| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Gemini Genomics PLC |
| 162 Science Park, Milton Road, Cambridge, United Kingdom CB4 0GH |
| Business Description | The company is a clinical genomic company that uses clinical and medical information as the starting point in the search for genes relevant to diseases, or disease genes. |
| Offering Information Company has | |||
| Trading As | GMNIY (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | American Depositary Receipts | Filing Date | 6/23/00 |
| Domestic Shares Offered | 6,000,000 | Offer Date | 7/25/00 |
| Foreign Shares Offered | 0 | Filing Range | $12.00 - $14.00 |
| Company Shares | 6,000,000 | Offer Price | $14.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.980 |
| Gross Proceeds | $84,000,000 | Selling | $0.580 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 62,895,220 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| SG Cowen | Lead Manager | (212) 495-6000 |
| Chase H&Q; | Co-manager | (415) 439-3626 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 3/31/98 | 3/31/99 | 3/31/00 | ||||
| Revenues | - | - | 0.000 | 0.198 | 0.164 | - | - |
| Income from Oper. | - | - | -7.899 | -10.694 | -15.390 | - | - |
| Net Income | - | - | -8.123 | -10.745 | -15.405 | - | - |
| E.P.S | - | - | -0.410 | -0.540 | -0.730 | - | - |
| Revenue Growth (%) | - | - | - | -17.172 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -11.72 | - | - | ||||
| Cash Flow - Inv. | -0.72 | - | - | ||||
| Cash Flow - Fin. | 13.94 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 3/31/00 | Financial Ratios | ||||
| Total Assets | 22.24 | Current Assets | 14.35 | Current Ratio | 1.95 |
| Total Liab. | 10.35 | Current Liab. | 7.36 | Debt Ratio | 46.54% |
| Total Equity | 11.89 | Working Cap. | 6.99 | Debt to Equity Ratio | 0.87 |
| Cash | 13.41 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for working capital and other general corporate purposes which may include funding research and development, entering into new clinical collaborations, expanding sales and marketing effort to license disease gene discoveries, and funding acquisitions, investments and partnerships. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Clifford Chance |
| Bank's Law Firm | Simpson, Thacher & Bartlett |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |